not sure they are smart enough to buy IMGN, but it would be nice if someone would get the bidding started as long as the final number starts with a 3. Not interested in a deal below the very high $20's at min. I think IMGN can hit that next year, or more without a bid. IMGN has cash, cash flow just getting started, 10 products, major partners and should get clinical results, mostly early stage on all, or most of these 10 nest year. 901 is a wild-card, expectations are very low, potential growth if results are positive and the drug considered commercially viable are huge. I hate to be patient, but it's a requirement with IMGN.
Check out Motley Fool article today:
With these two investments, AstraZeneca gains access to the two companies' ADC technologies, which could help it keep up with ImmunoGen (NASDAQ: IMGN ) and Seattle Genetics (NASDAQ: SGEN ) , which each gained FDA approval for their ADCs -- the breast cancer treatment Kadcyla (which Roche licensed from ImmunoGen) and the blood cancer drug Adcetris.